UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of June 2017
COMMISSION
FILE Number.
000-29338
CARDIOME
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
| Exhibit |
|
Description |
| |
|
|
| 99.1 |
|
News Release dated June 23, 2017 - Cardiome Pharma Corp. Announces Voting Results |
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
CARDIOME
PHARMA CORP. |
| |
(Registrant) |
| |
|
|
| Date: June 23, 2017 |
By: |
/s/
Justin Renz |
| |
|
Name: Justin Renz |
| |
|
Title: Chief Financial Officer |
Exhibit 99.1
Cardiome Pharma Corp. Announces Voting Results
NASDAQ:CRME
TSX:COM
VANCOUVER, June 23, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ:
CRME / TSX: COM) today announced the results of voting at its 2017 Annual General and Special Meeting of Shareholders held on June
20, 2017.
A total of 24,583,372 common shares were voted in connection
with the meeting, representing approximately 77.00% of the issued and outstanding common shares of the company. Shareholders voted
as follows:
Election of Directors
By resolution passed by ballot vote, the following six nominees
proposed by management were elected as directors of Cardiome to hold office until the next annual meeting of Shareholders or until
their successors are elected or appointed:
| Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
| Richard M. Glickman |
14,080,137 |
87.60% |
1,992,340 |
12.40% |
| W. James O'Shea |
15,466,194 |
96.23% |
606,283 |
3.77% |
| William L. Hunter |
15,543,529 |
96.71% |
528,948 |
3.29% |
| Mark H. Corrigan |
15,465,791 |
96.23% |
606,686 |
3.77% |
| Arthur H. Willms |
15,543,282 |
96.71% |
529,195 |
3.29% |
| Robert J. Meyer |
15,544,284 |
96.71% |
528,193 |
3.29% |
Appointment of Auditor
By resolution passed by show of hands, KMPG LLP, Chartered
Accountants, was appointed auditor of the company for the ensuing year.
Approval of Amendments to and Unallocated Entitlements
under the Restricted Share Unit Plan
By resolution passed by ballot vote, amendments to the Company's
Restricted Share Unit Plan were ratified, confirmed and approved, and the Restricted Share Unit Plan was re-approved and all unallocated
entitlements under the Restricted Share Unit Plan were approved, and the Company was granted the ability to continue granting restricted
share units under the Restricted Share Unit Plan until June 20, 2020.
| Votes For |
% Votes For |
Votes Against |
% Votes Against |
| 9,164,437 |
57.02% |
6,908,040 |
42.98% |
Approval of Amendments to and Unallocated Options under
the Incentive Stock Option Plan
By resolution passed by ballot vote, amendments to the Company's
Incentive Stock Option Plan were ratified, confirmed and approved and all unallocated options under the Incentive Stock Option
Plan were approved, and the Company was granted the ability to continue granting options under the Incentive Stock Option Plan
until June 20, 2020.
| Votes For |
% Votes For |
Votes Against |
% Votes Against |
| 14,004,680 |
87.13% |
2,067,797 |
12.87% |
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies
that will improve the quality of life and health of patients suffering from disease. Cardiome has two marketed, in-hospital, cardiology
products, BRINAVESS® (vernakalant IV), approved in Europe, Canada, and other territories for the rapid conversion
of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIB/IIIa
inhibitor indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD® and
ESMOCARD LYO® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number
of cardiovascular indications, on behalf of their partner Amomed in select European markets. Cardiome has also licensed: XYDALBA™
(dalbavancin hydrochloride), a second generation, semi-synthetic lipoglycopeptide approved in the EU for the treatment of acute
bacterial skin and skin structure infections (ABSSSI) in adults for select European and Middle Eastern nations and Canada from
Allergan; and TREVYENT®, a development stage drug device combination that is under development for Pulmonary Arterial
Hypertension for Europe, the Middle East and for Canadian markets from SteadyMed Therapeutics.
Cardiome is traded on the NASDAQ Capital Market (CRME) and
the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect" and similar expressions.
Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2017
and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook
for, our operations, research and development and product and drug development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks,
uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and
include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other
regions in which we operate; market demand; technological changes that could impact our existing or future products; competition;
existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations;
availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities;
and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may
cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual
results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete
pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property
matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market
acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability
of capital to finance our activities. These and other risks are described in the Form 40F and associated documents filed March
29, 2017 (see for example, "Risk Factors" in the Annual Information Form for the year ended December 31, 2016), in the
Form 6-K filed May 15, 2017, and in our other filings with the Securities and Exchange Commission ("SEC") available at
www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors,
you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their
entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations
and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events
or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
View original content: http://www.newswire.ca/en/releases/archive/June2017/23/c6889.html
%CIK: 0001036141
For further information: Justin Renz, Cardiome Investor Relations,
(604) 677-6905 ext. 128 or Toll Free: 1-800-330-9928, Email: jrenz@cardiome.com
CO: Cardiome Pharma Corp.
CNW 08:00e 23-JUN-17
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024
